However, immunohistochemical staining revealed the predominance of aberrant NRF2 signaling in 48.68% of ESCC, much higher than this pathway's mutation rates reported in previous studies, indicating the involvement of other factors in NRF2 activation [10]. The gene discussed is NFE2L2; the disease is esophageal squamous cell carcinoma.